Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    NeuroSense Therapeutics L...

    NASDAQ: NRSN · Real-Time Price · USD
    2.48
    0.10 (4.20%)
    At close: Jun 16, 2025, 3:59 PM
    2.50
    0.70%
    Pre-market: Jun 17, 2025, 08:33 AM EDT

    NeuroSense Therapeutics Statistics

    Share Statistics

    NeuroSense Therapeutics has 23.99M shares outstanding. The number of shares has increased by 28.78% in one year.

    Shares Outstanding

    n/a
    		 23.99M

    Shares Change (YoY)

    n/a
    		 28.78%

    Shares Change (QoQ)

    n/a
    		 0.45%

    Owned by Institutions (%)

    n/a
    		 3.58%

    Shares Floating

    n/a
    		 17.38M

    Failed to Deliver (FTD) Shares

    n/a
    		 328

    FTD / Avg. Volume

    n/a
    		 0.13%

    Short Selling Information

    The latest short interest is 306.44K, so 1.28% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 306.44K

    Short % of Shares Out

    n/a
    		 1.28%

    Short % of Float

    n/a
    		 1.55%

    Short Ratio (days to cover)

    n/a
    		 1

    Valuation Ratios

    The PE ratio is -2.19 and the forward PE ratio is -11.9. NeuroSense Therapeutics's PEG ratio is 0.06.

    PE Ratio

    n/a
    		 -2.19

    Forward PE

    n/a
    		 -11.9

    PS Ratio

    n/a
    		 0

    Forward PS

    n/a
    		 0.3

    PB Ratio

    n/a
    		 8.64

    P/FCF Ratio

    n/a
    		 -2.2

    PEG Ratio

    n/a
    		 0.06
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for NeuroSense Therapeutics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 2.21, with a Debt / Equity ratio of 0.03.

    Current Ratio

    n/a
    		 2.21

    Quick Ratio

    n/a
    		 2.21

    Debt / Equity

    n/a
    		 0.03

    Debt / EBITDA

    n/a
    		 -0.01

    Debt / FCF

    n/a
    		 -0.01

    Interest Coverage

    n/a
    		 -31.84

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 n/a

    Profits Per Employee

    n/a
    		 $-600,588.24

    Employee Count

    n/a
    		 17

    Asset Turnover

    n/a
    		 0

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 n/a

    Effective Tax Rate

    n/a
    		 0%

    Stock Price Statistics

    The stock price has increased by 165.83% in the last 52 weeks. The beta is 1.6, so NeuroSense Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 1.6

    52-Week Price Change

    n/a
    		 165.83%

    50-Day Moving Average

    n/a
    		 1.35

    200-Day Moving Average

    n/a
    		 1.18

    Relative Strength Index (RSI)

    n/a
    		 81.05

    Average Volume (20 Days)

    n/a
    		 245,288

    Income Statement

    Revenue

    n/a
    		 n/a

    Gross Profit

    n/a
    		 -22K

    Operating Income

    n/a
    		 -9.9M

    Net Income

    n/a
    		 -10.21M

    EBITDA

    n/a
    		 -9.88M

    EBIT

    n/a
    		 -9.9M

    Earnings Per Share (EPS)

    n/a
    		 -0.55
    Full Income Statement

    Balance Sheet

    The company has 3.38M in cash and 73K in debt, giving a net cash position of 3.31M.

    Cash & Cash Equivalents

    n/a
    		 3.38M

    Total Debt

    n/a
    		 73K

    Net Cash

    n/a
    		 3.31M

    Retained Earnings

    n/a
    		 -36.66M

    Total Assets

    n/a
    		 4.58M

    Working Capital

    n/a
    		 2.41M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -10.13M and capital expenditures -3K, giving a free cash flow of -10.14M.

    Operating Cash Flow

    n/a
    		 -10.13M

    Capital Expenditures

    n/a
    		 -3K

    Free Cash Flow

    n/a
    		 -10.14M

    FCF Per Share

    n/a
    		 -0.54
    Full Cash Flow Statement

    Margins

    Gross Margin

    n/a
    		 n/a

    Operating Margin

    n/a
    		 n/a

    Pretax Margin

    n/a
    		 n/a

    Profit Margin

    n/a
    		 n/a

    EBITDA Margin

    n/a
    		 n/a

    EBIT Margin

    n/a
    		 n/a

    FCF Margin

    n/a
    		 n/a

    Dividends & Yields

    NRSN does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for NRSN is $14, which is 464.5% higher than the current price. The consensus rating is "Hold".

    Price Target

    n/a
    		 $14

    Price Target Difference

    n/a
    		 464.5%

    Analyst Consensus

    n/a
    		 Hold

    Analyst Count

    n/a
    		 2
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 -7

    Piotroski F-Score

    n/a
    		 2

    Add to Watchlist